Similar Search Results

Cost-Effectiveness Assessment of Orphan Drugs

Simoens, Steven; Picavet, Eline; Dooms, Marc; Cassiman, … - In: Applied Health Economics and Health Policy 11 (2013) 1, pp. 1-3

Persistent link: https://www.econbiz.de/10010848792

Drugs for rare diseases: Influence of orphan designation status on price

Picavet, Eline; Dooms, Marc; Cassiman, David; Simoens, … - In: Applied Health Economics and Health Policy 9 (2011) 4, pp. 275-279

The literature indicates that the expenditure on orphan drugs will be increasing over the coming years. The market for orphan drugs has inherent market characteristics that sometimes result in high prices. The aim of this study was to analyse whether awarding orphan designation status has an...

Persistent link: https://www.econbiz.de/10011000788

Drugs for Rare Diseases: Influence of Orphan Designation Status on Price

Picavet, Eline; Dooms, Marc; Cassiman, David; Simoens, … - In: Applied Health Economics and Health Policy 9 (2011) 4, pp. 275-279

Persistent link: https://www.econbiz.de/10010614274

Fostering practice-oriented and use-inspired science in biomedical research

Anckaert, Paul-Emmanuel; Cassiman, David; Cassiman, Bruno - In: Research policy : policy, management and economic … 49 (2020) 2, pp. 1-14

Persistent link: https://www.econbiz.de/10012430291

Simoens, Steven - 2011

Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to...

Persistent link: https://www.econbiz.de/10009447441